This Month in Process Manufacturing – March 2026

📚 New Blog Posts

A monthly update for process manufacturing leaders across food, pharmaceutical, nutraceutical, chemical, and personal care industries

🎯 EXECUTIVE BRIEF

March 2026 is shaping up as a pivotal month for mid-market process manufacturers ($5M–$50M revenue). Inflation continues to climb while M&A activity remains aggressive. The ISM Prices Paid Index surged to 72.1%, the highest level in nearly four years, reflecting rising raw material costs and global supply chain pressures.

Yet buyers remain active. Gilead paid $7.8B for Arcellx CAR-T manufacturing, while TreeHouse Foods—the largest US private-label manufacturer—went private for $2.9B. The message is clear: buyers are paying for verified manufacturing capacity and operational control, not just products or brands.

Companies with documented pricing power, robust margin stability, and operational discipline continue to command premium valuations despite macroeconomic pressures.

📊 BY THE NUMBERS

Manufacturing Expansion vs. Inflation

52.6% — ISM Manufacturing PMI (Purchasing Managers’ Index)
56.1% — New Orders Index (slightly up)
72.1% — Prices Paid Index (highest in nearly 4 years)
53.8% — Production Index (modest growth)

M&A Market Momentum

$13B+ — Process manufacturing deal value in February 2026
$7.8B — Gilead/Arcellx (CAR-T therapy)
$2.9B — TreeHouse Foods privatization
$2.2B — Sanofi/Dynavax (adult vaccines)

Sector-Specific Signals

$170B+ — Pharmaceutical patent cliff revenue at risk by 2032
80%+ — Radiopharma deals now include manufacturing or isotope integration
30–50% — Valuation premium for businesses with documented operational excellence

Implication: Manufacturing growth continues, but cost management and verified operational control are now critical for capturing buyer premiums.

🏭 MARCH 2026 PROCESS MANUFACTURING INSIGHTS

Pharmaceutical & Life Sciences

Patent cliff pressure and vertical integration accelerate acquisitions.
Gilead/Arcellx ($7.8B) demonstrates buyers prioritizing manufacturing ownership over licensing.
Sanofi/Dynavax ($2.2B) reinforces the vaccine manufacturing capacity trend.
Siegfried/Noramco acquisition highlights the scarcity of US-based large-scale custom pharma sites.
80%+ of radiopharma deals now include operational or isotope integration.

Buyer Focus: US-based manufacturing, vertical integration, next-gen platforms, and late-stage clinical assets.

Chemical Manufacturing (Specialty & Coatings)

Sector expansion persists despite raw material and tariff pressures.
PE and strategic buyers focus on repeatable formulations, operational discipline (>95% OTIF, <5% deviation), and US production assets.
Specialty chemical consolidation continues; EBITDA multiples remain high (5.5–6.5x) for integration-ready businesses.

Buyer Focus: Operational discipline, capacity control, pricing power.

Nutraceutical & Supplement Manufacturing

Contract manufacturing consolidation accelerates.
Metagenics/Symprove and FitLife/Irwin Naturals ($42.5M) reinforce CDMO consolidation.
AI-driven discovery and third-party certifications (NSF, USP, ConsumerLab) are now standard requirements.

Buyer Focus: Vertical integration, professional-grade formulations, recurring revenue, US manufacturing.

Food & Beverage Manufacturing

Private label and contract manufacturing continue consolidating.
TreeHouse Foods ($2.9B) and Refresco/SunOpta ($6.50/share) highlight scale and operational excellence premiums.
Demand remains resilient; manufacturers with diversified customers and pricing power benefit most.

Buyer Focus: Scale, operational discipline, pricing mechanisms.

Personal Care & Cosmetics

Strategic buyers continue selective acquisitions.
e.l.f. Beauty/Rhode ($1B) and Unilever divestitures show premium for founder-led, science-backed brands.
US manufacturing capabilities are increasingly valued amid tariffs and reshoring.

Buyer Focus: Founder-led, science-backed brands, US production, DTC performance metrics.

💸 NOTABLE DEALS — MARCH 2026

Sector	Deal	Value	Insight
Pharmaceutical	Gilead → Arcellx	$7.8B	Vertical integration, CAR-T production
Pharmaceutical	Sanofi → Dynavax	$2.2B	Vaccine capacity acquisition
Pharmaceutical	Siegfried → Noramco	N/A	US manufacturing site premium
Food & Beverage	Investindustrial → TreeHouse	$2.9B	Platform consolidation, operational scale
Food & Beverage	Refresco → SunOpta	$6.50/share	Functional beverage expansion
Nutraceutical	Metagenics → Symprove	N/A	CDMO consolidation
Nutraceutical	FitLife → Irwin Naturals	$42.5M	Recurring revenue model
Personal Care	e.l.f. Beauty → Rhode	Up to $1B	Founder-led, DTC growth
Personal Care	Unilever → Rare Beauty	N/A	Portfolio optimization

🎤 INDUSTRY VOICE

Location Premium in M&A: New Jersey pharma site commanded 7.8x EBITDA, 60% above average, due to scarcity and regulatory licensing.
Lesson Across Sectors: Geographic location and manufacturing capacity now drive premiums more than growth or customer base.

⚙️ WHAT BUYERS ARE REALLY PAYING FOR

Manufacturing Capacity Control — US-based production, vertical integration, limited site availability drives 15–40% premium.
Pricing Power Amid Inflation — Contract pass-throughs and documented mechanisms command 20–30% advantage.
Operational Discipline — Complete batch records, OTIF >95%, deviation <5%, 30–50% valuation premium.
Regulatory Compliance & Quality Systems — FDA, DEA, EPA, GMP compliance; incomplete documentation = 15–25% discount.

🔧 OPERATOR PLAYBOOK

Finance Leaders: Document pricing power, analyze inflation impact, update forecasts, prepare board presentations.
Operations Leaders: Audit batch records, optimize capacity, review supplier costs, minimize waste.
Technology/IT Leaders: Ensure ERP compatibility, assess real-time cost tracking, and maintain DR/BC plans.
R&D & Regulatory: Verify FSMA/DEA/USP/GMP compliance, update training, and maintain clinical validation records.
Cross-Functional: Inflation response, M&A readiness, pricing power, geographic advantage.

📜 POLICY & COMPLIANCE PULSE

Tariffs & Trade: US manufacturing location premiums 15–25% amid steel/aluminum cost pressures.
FDA: Pre-Check Program, advanced manufacturing guidance, FSMA 204 traceability (July 2028).
EPA: PFAS reporting, TSCA updates, emission compliance scrutiny.
Implication: Proactive compliance drives premium valuations; incomplete compliance discounts 15–25%.